|
|
|
June 17, 2004
Features
J&J's multidisciplinary drug discovery platform aims to give scientists access to more information - and the ability to make better decisions.
By Mark D. Uehling
IT experts face a dilemma: to buy a LIMS, build their own, or consider a third solution.
By Salvatore Salamone
| Strategic Insights: Intellectual Property and the Law |
|
| · |
Does "safe harbor" apply to preclinical research?
BY Hope Melville |
| · |
Ship your IP overseas and save a boatload.
By Stephanie McRae |
| · |
Suing isn't as rewarding as it may seem.
By Cathryn Campbell |
| · |
Rational-drug-design firms are now under patent scrutiny.
BY John Garvey and Michel Morency |
Horizons
Conversation: Michael French
Entelos' Michael French explains what powers the systems biology engine.
Company to Watch
IntegraGen is trying to get the laboriousness out of human genetics.
Departments
News & Analysis
Is There Such a Thing as Free EDC?
Genasense NDA Withdrawn
Sequences Set in Stone
Proteomics Goes to the Hospital
So Much Data, So Little Time
Agilent’s Answer to Change
RNAi Races Toward the Clinic
Columns
First Base | Kevin Davies
Mutations may explain patient responses to Iressa.
Inside the Box | Chris Dagdigian
Breaking up with RedHat is hard to do.
Nothing Ventured | Michael A. Greeley
How will the biomarker craze pan out? Place your bets.
Fully Equipped | Robert M. Frederickson
Microarray analysis reaches the desktop.
The Russell Transcript | John Russell
Is Nicholas Carr's book the Satanic Verses of IT?
|
|
|
|